3 analysts' median target is $985[FMP target], stock is $814, +21.0% upside potential. After Q2 +1.9% EPS beat[FMP earnings], the stock moved +16.5%.
B- = MoonshotScore 47[9-pillar formula] + Council 2/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].
Q4 consensus: revenue $101.3B[FMP est], EPS $11.56[FMP est]. 4 consecutive quarters of beat[FMP earnings].
Q2 EPS +1.9% beat[FMP] but the stock +16.5% D+1[FMP D+1]. Britt Vitalone promised $108.0M CapEx + a sequential decline in Q4 during the Q2 earnings call[Britt Vitalone capex transcript].
Watchlist
Prescription Technology Solutions Growth
prescription_technology_solutions_growth
In the Prescription Technology Solutions segment, revenues increased 9% to $1.4 billion, and operating profit rose 20% to $261 million.
"In the Prescription Technology Solutions segment, revenues increased 9% to $1.4 billion, driven by increased prescription volumes across our third-party logistics and technology services businesses. Operating profit rose 20% to $261 million, reflecting increased demand for access solutions, including prior authorization services for GLP-1 medications."
- Britt Vitalone, CFO - Q2 FY26 Earnings Call - November 5, 2025
Glp 1 Medication Revenue
glp_1_medication_revenue
Revenues from GLP-1 medications were $13.2 billion in the quarter, an increase of approximately $2.6 billion or 24% when compared to the prior year.
"Revenues from GLP-1 medications were $13.2 billion in the quarter, an increase of approximately $2.6 billion or 24% when compared to the prior year."
- Britt Vitalone, CFO - Q2 FY26 Earnings Call - November 5, 2025
Oncology Multispecialty Growth
oncology_multispecialty_growth
In the Oncology and Multispecialty segment, revenues increased 32% to $12 billion, driven by strong provider and specialty distribution growth.
"In the Oncology and Multispecialty segment, revenues increased 32% to $12 billion, driven by strong provider and specialty distribution growth, including contributions from acquisitions completed in the first quarter of fiscal 2026."
- Britt Vitalone, CFO - Q2 FY26 Earnings Call - November 5, 2025
Fy26 Eps Guidance Increase
fy26_eps_guidance_increase
McKesson is raising its fiscal 2026 adjusted earnings per diluted share guidance to $38.35 to $38.85, building on strong Q2 performance and confidence in the outlook for the remainder of the year.
"Given our first half performance and our confidence in the outlook for the year, we are raising our guidance on adjusted earnings per diluted share to $38.35 to $38.85."
- Brian Tyler, CEO - Q2 FY26 Earnings Call - November 5, 2025
Medical Surgical Solutions Outlook
medical_surgical_solutions_outlook
McKesson anticipates revenue and operating profit in the Medical-Surgical Solutions segment to be at the low end of the 2% to 6% growth range due to lower illness season product volumes.
"Due to lower-than-anticipated illness season product volumes compared to the prior year, including vaccines and testing and lower volumes across ambulatory and extended care settings, we anticipate revenue and operating profit at the low end of 2% to 6% growth."
- Britt Vitalone, CFO - Q2 FY26 Earnings Call - November 5, 2025
Stock Expert AI - Methodology
9-pillar methodology. Revenue Growth and Cash Runway strong. Gross Margin weak.
How is it calculated? ->6 investor frameworks. 2 bullish (Ray Dalio, Jim Simons), 1 bearish (Ken Griffin), 3 neutral (Klarman, Buffett, Munger).
How is it calculated? ->Quality business, trading at fair value.
How is it calculated? ->Past Performance
Q2 (November 5, 2025): EPS $9.34 vs $9.17 est[FMP], +1.9% beat. D+1 movement: +16.5%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.
Q2: EPS $9.34 vs $9.17 beat[FMP], stock +16.5% D+1[FMP].
No RPO/backlog concentration disclosed in Q2 earnings call.
Q2 CapEx $108.0M[FMP cashflow]. Q2 op margin 1.5%[FMP op margin] - this level in Q4 is sensitive to CapEx revision risk.
Not advice - a structural framework for earnings night. Decision discipline is yours.
Market Outlook
You read it in 5 minutes. When the numbers come out on Thursday evening - you know what you're looking at.
Data arrives at night. The framework is ready now.
Data arrives on Thursday evening. The framework is ready on this page: Q4 EPS threshold $11.56[FMP], CapEx threshold "below $108.0M"[Britt Vitalone]. Two anchors, three scenarios.
Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).
Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts
Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing
Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore 9-pillar + Insider tracker + Technical levels - all in one platform, for every stock.
Educational tool, not investment advice. Past performance does not guarantee future results.
Calendar
DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.
This MCK (MCK) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.
Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.